nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenobarbital—CYP1B1—Mitoxantrone—lymphatic system cancer	0.109	0.122	CbGbCtD
Phenobarbital—ABCC3—Vincristine—lymphatic system cancer	0.0867	0.0968	CbGbCtD
Phenobarbital—ABCC1—Mitoxantrone—lymphatic system cancer	0.0773	0.0864	CbGbCtD
Phenobarbital—ABCB11—Vincristine—lymphatic system cancer	0.0749	0.0837	CbGbCtD
Phenobarbital—ABCC1—Vincristine—lymphatic system cancer	0.0532	0.0595	CbGbCtD
Phenobarbital—ABCC3—Methotrexate—lymphatic system cancer	0.0525	0.0586	CbGbCtD
Phenobarbital—CYP1A2—Carmustine—lymphatic system cancer	0.0454	0.0507	CbGbCtD
Phenobarbital—CYP3A5—Teniposide—lymphatic system cancer	0.041	0.0458	CbGbCtD
Phenobarbital—ABCC2—Vincristine—lymphatic system cancer	0.0394	0.044	CbGbCtD
Phenobarbital—CYP2E1—Mitoxantrone—lymphatic system cancer	0.0369	0.0412	CbGbCtD
Phenobarbital—CYP2C19—Teniposide—lymphatic system cancer	0.0331	0.0369	CbGbCtD
Phenobarbital—ABCC1—Methotrexate—lymphatic system cancer	0.0322	0.036	CbGbCtD
Phenobarbital—CYP2C9—Teniposide—lymphatic system cancer	0.0275	0.0307	CbGbCtD
Phenobarbital—CYP3A7—Vincristine—lymphatic system cancer	0.0263	0.0294	CbGbCtD
Phenobarbital—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.0263	0.0294	CbGbCtD
Phenobarbital—ABCC2—Methotrexate—lymphatic system cancer	0.0238	0.0266	CbGbCtD
Phenobarbital—CYP3A5—Vincristine—lymphatic system cancer	0.0197	0.022	CbGbCtD
Phenobarbital—ABCB1—Mitoxantrone—lymphatic system cancer	0.0187	0.0208	CbGbCtD
Phenobarbital—CYP3A4—Cytarabine—lymphatic system cancer	0.0162	0.0181	CbGbCtD
Phenobarbital—CYP3A4—Teniposide—lymphatic system cancer	0.016	0.0179	CbGbCtD
Phenobarbital—ABCB1—Vincristine—lymphatic system cancer	0.0128	0.0143	CbGbCtD
Phenobarbital—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0112	0.0125	CbGbCtD
Phenobarbital—ABCB1—Methotrexate—lymphatic system cancer	0.00777	0.00869	CbGbCtD
Phenobarbital—CYP3A4—Vincristine—lymphatic system cancer	0.00769	0.0086	CbGbCtD
Phenobarbital—Blister—Mechlorethamine—lymphatic system cancer	0.00397	0.0378	CcSEcCtD
Phenobarbital—Hypoxia—Fludarabine—lymphatic system cancer	0.00292	0.0278	CcSEcCtD
Phenobarbital—Extravasation—Teniposide—lymphatic system cancer	0.00242	0.023	CcSEcCtD
Phenobarbital—Anaemia megaloblastic—Methotrexate—lymphatic system cancer	0.00233	0.0222	CcSEcCtD
Phenobarbital—Dermatitis bullous—Mechlorethamine—lymphatic system cancer	0.00217	0.0207	CcSEcCtD
Phenobarbital—Hypocalcaemia—Fludarabine—lymphatic system cancer	0.00202	0.0193	CcSEcCtD
Phenobarbital—Respiratory failure—Fludarabine—lymphatic system cancer	0.00189	0.018	CcSEcCtD
Phenobarbital—Coma—Fludarabine—lymphatic system cancer	0.00169	0.0161	CcSEcCtD
Phenobarbital—Nystagmus—Vincristine—lymphatic system cancer	0.00158	0.0151	CcSEcCtD
Phenobarbital—Extravasation—Bleomycin—lymphatic system cancer	0.00156	0.0148	CcSEcCtD
Phenobarbital—Necrosis—Carmustine—lymphatic system cancer	0.00151	0.0144	CcSEcCtD
Phenobarbital—Necrosis—Mitoxantrone—lymphatic system cancer	0.0014	0.0134	CcSEcCtD
Phenobarbital—Extravasation—Carmustine—lymphatic system cancer	0.00136	0.0129	CcSEcCtD
Phenobarbital—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.00136	0.0129	CcSEcCtD
Phenobarbital—Extravasation—Vincristine—lymphatic system cancer	0.0013	0.0124	CcSEcCtD
Phenobarbital—Thinking abnormal—Carmustine—lymphatic system cancer	0.00129	0.0123	CcSEcCtD
Phenobarbital—Extravasation—Mitoxantrone—lymphatic system cancer	0.00126	0.012	CcSEcCtD
Phenobarbital—Toxic epidermal necrolysis—Fludarabine—lymphatic system cancer	0.00121	0.0115	CcSEcCtD
Phenobarbital—Hypocalcaemia—Mitoxantrone—lymphatic system cancer	0.0012	0.0115	CcSEcCtD
Phenobarbital—Injection site reaction—Carmustine—lymphatic system cancer	0.00118	0.0112	CcSEcCtD
Phenobarbital—Respiratory failure—Vincristine—lymphatic system cancer	0.00115	0.011	CcSEcCtD
Phenobarbital—Depressed level of consciousness—Carmustine—lymphatic system cancer	0.00114	0.0109	CcSEcCtD
Phenobarbital—Vertigo—Mechlorethamine—lymphatic system cancer	0.00112	0.0107	CcSEcCtD
Phenobarbital—Coma—Carmustine—lymphatic system cancer	0.00108	0.0103	CcSEcCtD
Phenobarbital—Coma—Vincristine—lymphatic system cancer	0.00103	0.00985	CcSEcCtD
Phenobarbital—Mental disability—Carmustine—lymphatic system cancer	0.00103	0.0098	CcSEcCtD
Phenobarbital—Stevens-Johnson syndrome—Fludarabine—lymphatic system cancer	0.00103	0.00979	CcSEcCtD
Phenobarbital—Renal failure—Fludarabine—lymphatic system cancer	0.00102	0.0097	CcSEcCtD
Phenobarbital—Erythema multiforme—Fludarabine—lymphatic system cancer	0.000879	0.00838	CcSEcCtD
Phenobarbital—Hypoxia—Methotrexate—lymphatic system cancer	0.000864	0.00824	CcSEcCtD
Phenobarbital—Agitation—Teniposide—lymphatic system cancer	0.000847	0.00807	CcSEcCtD
Phenobarbital—Ataxia—Carmustine—lymphatic system cancer	0.000809	0.00771	CcSEcCtD
Phenobarbital—Ataxia—Vincristine—lymphatic system cancer	0.000772	0.00736	CcSEcCtD
Phenobarbital—Confusional state—Teniposide—lymphatic system cancer	0.000758	0.00722	CcSEcCtD
Phenobarbital—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.000751	0.00716	CcSEcCtD
Phenobarbital—Agitation—Fludarabine—lymphatic system cancer	0.000744	0.00709	CcSEcCtD
Phenobarbital—Hypotension—Teniposide—lymphatic system cancer	0.000703	0.00669	CcSEcCtD
Phenobarbital—Necrosis—Methotrexate—lymphatic system cancer	0.0007	0.00667	CcSEcCtD
Phenobarbital—Arthralgia—Fludarabine—lymphatic system cancer	0.000689	0.00657	CcSEcCtD
Phenobarbital—Myalgia—Fludarabine—lymphatic system cancer	0.000689	0.00657	CcSEcCtD
Phenobarbital—Confusional state—Fludarabine—lymphatic system cancer	0.000666	0.00635	CcSEcCtD
Phenobarbital—Renal failure—Carmustine—lymphatic system cancer	0.000652	0.00621	CcSEcCtD
Phenobarbital—Vomiting—Mechlorethamine—lymphatic system cancer	0.000648	0.00618	CcSEcCtD
Phenobarbital—Apnoea—Methotrexate—lymphatic system cancer	0.000648	0.00617	CcSEcCtD
Phenobarbital—Rash—Mechlorethamine—lymphatic system cancer	0.000643	0.00613	CcSEcCtD
Phenobarbital—Dermatitis—Mechlorethamine—lymphatic system cancer	0.000642	0.00612	CcSEcCtD
Phenobarbital—Extravasation—Methotrexate—lymphatic system cancer	0.000629	0.006	CcSEcCtD
Phenobarbital—Feeling abnormal—Teniposide—lymphatic system cancer	0.00062	0.0059	CcSEcCtD
Phenobarbital—Drowsiness—Mitoxantrone—lymphatic system cancer	0.000616	0.00587	CcSEcCtD
Phenobarbital—Renal failure—Mitoxantrone—lymphatic system cancer	0.000606	0.00577	CcSEcCtD
Phenobarbital—Nausea—Mechlorethamine—lymphatic system cancer	0.000606	0.00577	CcSEcCtD
Phenobarbital—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.000602	0.00574	CcSEcCtD
Phenobarbital—Urticaria—Teniposide—lymphatic system cancer	0.000597	0.00569	CcSEcCtD
Phenobarbital—Body temperature increased—Teniposide—lymphatic system cancer	0.000594	0.00566	CcSEcCtD
Phenobarbital—Erythema—Bleomycin—lymphatic system cancer	0.000594	0.00566	CcSEcCtD
Phenobarbital—Hallucination—Carmustine—lymphatic system cancer	0.000592	0.00564	CcSEcCtD
Phenobarbital—Hallucination—Vincristine—lymphatic system cancer	0.000565	0.00539	CcSEcCtD
Phenobarbital—Constipation—Fludarabine—lymphatic system cancer	0.000565	0.00538	CcSEcCtD
Phenobarbital—Pain—Fludarabine—lymphatic system cancer	0.000565	0.00538	CcSEcCtD
Phenobarbital—Bradycardia—Mitoxantrone—lymphatic system cancer	0.000563	0.00537	CcSEcCtD
Phenobarbital—Respiratory failure—Methotrexate—lymphatic system cancer	0.000559	0.00533	CcSEcCtD
Phenobarbital—Hypersensitivity—Teniposide—lymphatic system cancer	0.000554	0.00528	CcSEcCtD
Phenobarbital—Hepatitis—Mitoxantrone—lymphatic system cancer	0.000553	0.00527	CcSEcCtD
Phenobarbital—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000545	0.00519	CcSEcCtD
Phenobarbital—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.00053	0.00505	CcSEcCtD
Phenobarbital—Body temperature increased—Fludarabine—lymphatic system cancer	0.000522	0.00498	CcSEcCtD
Phenobarbital—Erythema—Carmustine—lymphatic system cancer	0.000518	0.00494	CcSEcCtD
Phenobarbital—Myalgia—Bleomycin—lymphatic system cancer	0.000505	0.00482	CcSEcCtD
Phenobarbital—Coma—Methotrexate—lymphatic system cancer	0.000502	0.00478	CcSEcCtD
Phenobarbital—Confusional state—Bleomycin—lymphatic system cancer	0.000489	0.00465	CcSEcCtD
Phenobarbital—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000487	0.00464	CcSEcCtD
Phenobarbital—Erythema—Mitoxantrone—lymphatic system cancer	0.000482	0.00459	CcSEcCtD
Phenobarbital—Vomiting—Teniposide—lymphatic system cancer	0.000478	0.00455	CcSEcCtD
Phenobarbital—Agitation—Carmustine—lymphatic system cancer	0.000476	0.00454	CcSEcCtD
Phenobarbital—Rash—Teniposide—lymphatic system cancer	0.000474	0.00452	CcSEcCtD
Phenobarbital—Dermatitis—Teniposide—lymphatic system cancer	0.000474	0.00451	CcSEcCtD
Phenobarbital—Headache—Teniposide—lymphatic system cancer	0.000471	0.00449	CcSEcCtD
Phenobarbital—Agitation—Vincristine—lymphatic system cancer	0.000455	0.00433	CcSEcCtD
Phenobarbital—Hypotension—Bleomycin—lymphatic system cancer	0.000453	0.00431	CcSEcCtD
Phenobarbital—Nausea—Teniposide—lymphatic system cancer	0.000447	0.00426	CcSEcCtD
Phenobarbital—Vertigo—Vincristine—lymphatic system cancer	0.000444	0.00423	CcSEcCtD
Phenobarbital—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000441	0.00421	CcSEcCtD
Phenobarbital—Myalgia—Carmustine—lymphatic system cancer	0.000441	0.0042	CcSEcCtD
Phenobarbital—Anxiety—Carmustine—lymphatic system cancer	0.00044	0.00419	CcSEcCtD
Phenobarbital—Confusional state—Carmustine—lymphatic system cancer	0.000426	0.00406	CcSEcCtD
Phenobarbital—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.000422	0.00402	CcSEcCtD
Phenobarbital—Myalgia—Vincristine—lymphatic system cancer	0.000421	0.00401	CcSEcCtD
Phenobarbital—Vomiting—Fludarabine—lymphatic system cancer	0.00042	0.004	CcSEcCtD
Phenobarbital—Rash—Fludarabine—lymphatic system cancer	0.000417	0.00397	CcSEcCtD
Phenobarbital—Dermatitis—Fludarabine—lymphatic system cancer	0.000416	0.00397	CcSEcCtD
Phenobarbital—Pain—Bleomycin—lymphatic system cancer	0.000414	0.00395	CcSEcCtD
Phenobarbital—Headache—Fludarabine—lymphatic system cancer	0.000414	0.00394	CcSEcCtD
Phenobarbital—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00041	0.00391	CcSEcCtD
Phenobarbital—Myalgia—Mitoxantrone—lymphatic system cancer	0.00041	0.00391	CcSEcCtD
Phenobarbital—Anxiety—Mitoxantrone—lymphatic system cancer	0.000409	0.00389	CcSEcCtD
Phenobarbital—Lethargy—Methotrexate—lymphatic system cancer	0.000407	0.00388	CcSEcCtD
Phenobarbital—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000399	0.0038	CcSEcCtD
Phenobarbital—Confusional state—Mitoxantrone—lymphatic system cancer	0.000396	0.00378	CcSEcCtD
Phenobarbital—Hypotension—Carmustine—lymphatic system cancer	0.000395	0.00377	CcSEcCtD
Phenobarbital—Nausea—Fludarabine—lymphatic system cancer	0.000393	0.00374	CcSEcCtD
Phenobarbital—Shock—Mitoxantrone—lymphatic system cancer	0.000387	0.00369	CcSEcCtD
Phenobarbital—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000385	0.00367	CcSEcCtD
Phenobarbital—Urticaria—Bleomycin—lymphatic system cancer	0.000385	0.00367	CcSEcCtD
Phenobarbital—Body temperature increased—Bleomycin—lymphatic system cancer	0.000383	0.00365	CcSEcCtD
Phenobarbital—Irritability—Methotrexate—lymphatic system cancer	0.00038	0.00362	CcSEcCtD
Phenobarbital—Mood swings—Methotrexate—lymphatic system cancer	0.000378	0.0036	CcSEcCtD
Phenobarbital—Hypotension—Vincristine—lymphatic system cancer	0.000377	0.00359	CcSEcCtD
Phenobarbital—Somnolence—Carmustine—lymphatic system cancer	0.000376	0.00358	CcSEcCtD
Phenobarbital—Ataxia—Methotrexate—lymphatic system cancer	0.000375	0.00357	CcSEcCtD
Phenobarbital—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000368	0.0035	CcSEcCtD
Phenobarbital—Hypotension—Mitoxantrone—lymphatic system cancer	0.000367	0.0035	CcSEcCtD
Phenobarbital—Constipation—Carmustine—lymphatic system cancer	0.000362	0.00345	CcSEcCtD
Phenobarbital—Pain—Carmustine—lymphatic system cancer	0.000362	0.00345	CcSEcCtD
Phenobarbital—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000359	0.00342	CcSEcCtD
Phenobarbital—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000358	0.00341	CcSEcCtD
Phenobarbital—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000357	0.0034	CcSEcCtD
Phenobarbital—Somnolence—Mitoxantrone—lymphatic system cancer	0.00035	0.00333	CcSEcCtD
Phenobarbital—Feeling abnormal—Carmustine—lymphatic system cancer	0.000349	0.00332	CcSEcCtD
Phenobarbital—Pain—Vincristine—lymphatic system cancer	0.000345	0.00329	CcSEcCtD
Phenobarbital—Constipation—Vincristine—lymphatic system cancer	0.000345	0.00329	CcSEcCtD
Phenobarbital—Asthma—Methotrexate—lymphatic system cancer	0.000344	0.00328	CcSEcCtD
Phenobarbital—Constipation—Mitoxantrone—lymphatic system cancer	0.000336	0.0032	CcSEcCtD
Phenobarbital—Pain—Mitoxantrone—lymphatic system cancer	0.000336	0.0032	CcSEcCtD
Phenobarbital—Body temperature increased—Carmustine—lymphatic system cancer	0.000334	0.00319	CcSEcCtD
Phenobarbital—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000324	0.00309	CcSEcCtD
Phenobarbital—Body temperature increased—Vincristine—lymphatic system cancer	0.000319	0.00304	CcSEcCtD
Phenobarbital—Urticaria—Mitoxantrone—lymphatic system cancer	0.000312	0.00298	CcSEcCtD
Phenobarbital—Hypersensitivity—Carmustine—lymphatic system cancer	0.000312	0.00297	CcSEcCtD
Phenobarbital—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000311	0.00296	CcSEcCtD
Phenobarbital—Vomiting—Bleomycin—lymphatic system cancer	0.000308	0.00294	CcSEcCtD
Phenobarbital—Drowsiness—Methotrexate—lymphatic system cancer	0.000307	0.00293	CcSEcCtD
Phenobarbital—Rash—Bleomycin—lymphatic system cancer	0.000306	0.00291	CcSEcCtD
Phenobarbital—Dermatitis—Bleomycin—lymphatic system cancer	0.000305	0.00291	CcSEcCtD
Phenobarbital—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000305	0.0029	CcSEcCtD
Phenobarbital—Renal failure—Methotrexate—lymphatic system cancer	0.000302	0.00288	CcSEcCtD
Phenobarbital—Hypersensitivity—Vincristine—lymphatic system cancer	0.000297	0.00283	CcSEcCtD
Phenobarbital—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00029	0.00276	CcSEcCtD
Phenobarbital—Nausea—Bleomycin—lymphatic system cancer	0.000288	0.00274	CcSEcCtD
Phenobarbital—Dizziness—Carmustine—lymphatic system cancer	0.00028	0.00266	CcSEcCtD
Phenobarbital—Hepatitis—Methotrexate—lymphatic system cancer	0.000276	0.00263	CcSEcCtD
Phenobarbital—Vomiting—Carmustine—lymphatic system cancer	0.000269	0.00256	CcSEcCtD
Phenobarbital—Dizziness—Vincristine—lymphatic system cancer	0.000267	0.00254	CcSEcCtD
Phenobarbital—Rash—Carmustine—lymphatic system cancer	0.000267	0.00254	CcSEcCtD
Phenobarbital—Dermatitis—Carmustine—lymphatic system cancer	0.000266	0.00254	CcSEcCtD
Phenobarbital—Headache—Carmustine—lymphatic system cancer	0.000265	0.00252	CcSEcCtD
Phenobarbital—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000261	0.00248	CcSEcCtD
Phenobarbital—Vomiting—Vincristine—lymphatic system cancer	0.000257	0.00245	CcSEcCtD
Phenobarbital—Rash—Vincristine—lymphatic system cancer	0.000255	0.00243	CcSEcCtD
Phenobarbital—Dermatitis—Vincristine—lymphatic system cancer	0.000254	0.00242	CcSEcCtD
Phenobarbital—Headache—Vincristine—lymphatic system cancer	0.000253	0.00241	CcSEcCtD
Phenobarbital—Nausea—Carmustine—lymphatic system cancer	0.000251	0.00239	CcSEcCtD
Phenobarbital—Vomiting—Mitoxantrone—lymphatic system cancer	0.00025	0.00238	CcSEcCtD
Phenobarbital—Rash—Mitoxantrone—lymphatic system cancer	0.000248	0.00236	CcSEcCtD
Phenobarbital—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000248	0.00236	CcSEcCtD
Phenobarbital—Headache—Mitoxantrone—lymphatic system cancer	0.000246	0.00235	CcSEcCtD
Phenobarbital—Erythema—Methotrexate—lymphatic system cancer	0.00024	0.00229	CcSEcCtD
Phenobarbital—Nausea—Vincristine—lymphatic system cancer	0.00024	0.00228	CcSEcCtD
Phenobarbital—Nausea—Mitoxantrone—lymphatic system cancer	0.000234	0.00223	CcSEcCtD
Phenobarbital—Vertigo—Methotrexate—lymphatic system cancer	0.000216	0.00205	CcSEcCtD
Phenobarbital—Arthralgia—Methotrexate—lymphatic system cancer	0.000204	0.00195	CcSEcCtD
Phenobarbital—Myalgia—Methotrexate—lymphatic system cancer	0.000204	0.00195	CcSEcCtD
Phenobarbital—Confusional state—Methotrexate—lymphatic system cancer	0.000198	0.00188	CcSEcCtD
Phenobarbital—Hypotension—Methotrexate—lymphatic system cancer	0.000183	0.00174	CcSEcCtD
Phenobarbital—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000178	0.0017	CcSEcCtD
Phenobarbital—Somnolence—Methotrexate—lymphatic system cancer	0.000174	0.00166	CcSEcCtD
Phenobarbital—Pain—Methotrexate—lymphatic system cancer	0.000168	0.0016	CcSEcCtD
Phenobarbital—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000161	0.00154	CcSEcCtD
Phenobarbital—Urticaria—Methotrexate—lymphatic system cancer	0.000156	0.00148	CcSEcCtD
Phenobarbital—Body temperature increased—Methotrexate—lymphatic system cancer	0.000155	0.00148	CcSEcCtD
Phenobarbital—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000144	0.00138	CcSEcCtD
Phenobarbital—Dizziness—Methotrexate—lymphatic system cancer	0.00013	0.00123	CcSEcCtD
Phenobarbital—Vomiting—Methotrexate—lymphatic system cancer	0.000125	0.00119	CcSEcCtD
Phenobarbital—Rash—Methotrexate—lymphatic system cancer	0.000124	0.00118	CcSEcCtD
Phenobarbital—Dermatitis—Methotrexate—lymphatic system cancer	0.000123	0.00118	CcSEcCtD
Phenobarbital—Headache—Methotrexate—lymphatic system cancer	0.000123	0.00117	CcSEcCtD
Phenobarbital—Nausea—Methotrexate—lymphatic system cancer	0.000116	0.00111	CcSEcCtD
